1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Price Gap Between Brand And Generic Drugs Widening – Express Scripts

 
• By Gregory Twachtman

In its inaugural Drug Trends Quarterly, Express Scripts finds that prices for branded pharmaceuticals are growing at a faster pace than the Consumer Price Index and the gap between branded and generic drug prices is at its widest point since the pharmacy benefit manager began calculating price indexes for each in 2008.

The price gap between branded and generic pharmaceuticals is at its widest point since 2008 when Express Scripts Holding Co. began calculating indexes for each, according to data released by pharmacy benefit manager Nov. 28.

The inaugural Drug Trends Quarterly publication says the Brand Prescription Price Index, a measurement of the prices for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 
• By Michael McCaughan

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

US FDA Pediatric Adcomm To Examine HPV, Flu, Dengue Vaccines: No News Is Good News?

 
• By Sue Sutter

Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.